WS #12206

From 500 msgs · 7 key-dev

The US-Iran conflict continues to escalate with new US missile strikes near Qeshm Island and drone interceptions over Erbil, Iraq, yet oil prices remain subdued near session lows, suggesting potential government intervention in oil markets. A key counter-signal emerges: China has reduced its oil purchases by 5 million barrels per day, offsetting supply disruptions from the Strait of Hormuz closure. This explains the muted oil price reaction and dampens the bullish energy thesis. Meanwhile, bond traders are bailing on Fed hike wagers due to softer inflation outlook, which counters the inflation narrative from oil spikes. The narrative arc is ESCALATING on the US-Iran conflict, but the oil price action and China demand drop act as significant counterweights. In tech, TSMC's Q2 beat was overshadowed by a capex guidance increase to $60-64B, pressuring semiconductor stocks. Apple Intelligence received approval in China but with Alibaba's Qwen instead of Google Gemini, a positive for AAPL and BABA. A major M&A deal emerged: Uber's $14.8B offer for Delivery Hero, creating the largest food delivery platform outside China, with implications for UBER, DHER, and competitors. UnitedHealth's strong Q2 beat and raised guidance is a positive signal for the healthcare sector. Dark pool alerts show large institutional buying in NVDA ($391.63M) and AMD ($178.97M), suggesting accumulation despite sector weakness. A bullish META call options block ($112.38M) indicates institutional positioning for upside.

Topics

Key developments

  • US missile strikes near Qeshm Island escalate Iran conflict; oil prices muted as China cuts purchases by 5M bpd
  • TSMC Q2 net profit record $19.15B, but capex guidance raised to $60-64B pressures semiconductor stocks
  • Apple Intelligence approved in China with Alibaba's Qwen model; bullish for AAPL and BABA
  • Uber agrees to acquire Delivery Hero for €41.5/share, creating largest food delivery platform outside China
  • UnitedHealth Q2 adjusted EPS $6.38 beats by $1.46, raises 2026 guidance; bullish for managed care
  • META bullish call options block: 15,500 contracts at $700 strike, $112.38M premium
  • Merck receives FDA approval for Lipfendra, new cholesterol drug alternative to statins